Lactic acid bacteria, composition for improving intestinal microbial strain composition, and product and use of lactic acid bacteria
By using exosomes secreted by Pediococcus lactis to regulate gut microbiota, the colonization difficulties and safety risks of gut microbiota regulation in existing technologies have been resolved, achieving healthy restoration of gut microbiota and promotion of the growth of specific bacteria, especially for the improvement of Alzheimer's disease.
Patent Information
- Application Number
- CN202311673528.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-11-08
- Filing Date
- 2023-12-07
- Publication Date
- 2024-11-12
AI Technical Summary
Existing methods for regulating the gut microbiota, such as probiotics and fecal microbiota transplantation, suffer from difficulties in colonization, complex procedures, and safety risks. They cannot effectively regulate the composition of the gut microbiota, and their impact on related diseases such as obesity, inflammatory bowel disease, autism, and neurodegenerative diseases is limited.
Extracellular oozosomes, constructed from nano-sized spherical lipid bilayer membranes and containing nucleic acid and protein components, are secreted by Pediococcus acidilactici NCIMB 44102. They regulate the composition of the intestinal microbiota via oral administration, affecting the growth of Firmicutes and Bacteroidetes, and promoting the growth of specific bacterial classes and families.
It safely and effectively improves the composition of gut microbiota, restoring the composition of microbiota in a healthy state. In particular, it has a significant effect on improving the gut microbiota of Alzheimer's disease gene-transfected mice, promoting the growth of Lactobacillus acidophilus and its uptake by specific gut bacteria, thereby improving gut health.
Smart Images

Figure CN118931752A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of improving the composition of intestinal microbial species, and in particular to the technical field of a composition comprising a novel lactic acid bacterium and / or the extracellular vesicles secreted by the lactic acid bacterium for improving the composition of intestinal microbial species. Background Art
[0002] The composition and changes of intestinal microorganisms are related to human health. A complex nervous system is distributed in the intestine. The intestine and the brain are connected and influenced by each other through the gut-brain axis. Intestinal microorganisms produce metabolites and other brain neurotransmitters, which affect intestinal cells and immune cells, and thus affect the host's gastrointestinal function, and even behavioral and emotional expressions.
[0003] Intestinal microbes include a variety of symbiotic microorganisms, which are mainly composed of bacteria, most of which are absolute anaerobes, and there are four main categories: Bacteroidetes, Firmicutes, Actinobacteria, and Proteobacteria. In addition, studies have found that the ratio of Bacteroidetes to Firmicutes changes with disease. The intestinal flora of healthy people contains a large number of Bacteroidetes, while the intestinal flora of disease patients contains a large number of Firmicutes. The Bacteroidetes flora in the intestines of obese patients is greatly reduced, including a reduction in many intestinal probiotics. The number of Bacteroides thetaiotaomicron in the intestines of obese people is lower, and it is correlated with obesity-related metabolites and hormonal changes. It is highly feasible to identify key microorganisms associated with the disease and use them as target treatment. At the same time, intestinal microorganisms play an important role in maintaining intestinal homeostasis and the integrity of the mucosal immune system. Intestinal microorganisms help maintain intestinal integrity and regulate intestinal barrier permeability. Evidence has shown that microbial flora imbalance and changes are associated with many diseases and functional disorders, such as obesity, inflammatory bowel disease (IBD), autism, and neurodegenerative diseases. Specific intestinal microorganisms will change with different degrees of disease (Liu et al. Nature Medicine 2017, 23, 859-868; Hall et al. Genome Medicine 2017, 9, 103; Finegold et al. Anaerobe 2010, 16, 444-453; Scheperjans et al. Movement Disorders 2015, 30, 350-358).
[0004] Currently, the regulation of gastrointestinal flora is mostly achieved by directly taking probiotics, which increase the number of good bacteria and inhibit bad bacteria through the colonization of probiotics. Currently, there is also a method of transplanting normal flora into the host's digestive system through faecal microbiota transplant (FMT).
[0005] However, probiotics generally have the problem of not being able to colonize, which limits their impact on the flora. And FMT treatment still has many shortcomings and its safety is controversial. At present, the main routes of fecal microbiota transplantation include the upper gastrointestinal tract, the middle gastrointestinal tract and the lower gastrointestinal tract; the fecal microbiota transplantation through the upper gastrointestinal tract is through oral fecal microbiota, but its disadvantage is that the microorganisms are easily affected by bile salts, the fecal microbiota transplantation through the middle gastrointestinal tract is operated through nasal tubes or skin endoscopic gastric tubes, and its disadvantages are that if the operation is improper, aspiration and reflux may occur, and the microorganisms will also be affected by bile salts, and the fecal microbiota transplantation through the lower gastrointestinal tract is operated through colonoscopy, enema, and endoscopic intestinal catheterization, and its disadvantages are that fecal microbiota can only cover the sigmoid colon and multiple fecal microbiota transplants are required. Although FMT was considered a safe treatment method in the past, according to the latest clinical reports and examples reported by the US Food and Drug Administration, a patient received fecal microbiota from a health provider, but the Escherichia coli in his fecal microbiota already had multidrug resistance genes, which caused the death of the FMT recipient. In addition, current technology is still unable to effectively judge the drug-resistant genes in the bacteria of healthy FMT donors, so FMT still has potential risks.
[0006] In view of the limitations and shortcomings of the current gastrointestinal flora regulation methods, and the fact that the composition and changes of intestinal microorganisms are closely related to human health and many diseases, the inventors of this case hope to use a nano-sized spherical lipid bilayer (lipid bilayer) and extracellular vesicles (EVs) coated with nucleic acids and proteins, etc., to interact with neighboring bacteria, thereby safely and effectively regulating the composition and changes of intestinal microorganisms. In view of this, the inventors of this case have made great efforts to study and invent, and finally developed the novel lactic acid bacteria of the present invention, the composition for improving the composition of intestinal microbial strains, and the products and uses of the lactic acid bacteria, achieving the effect of effectively improving intestinal health through the extracellular vesicles secreted by trace microorganisms. Summary of the invention
[0007] The main purpose of the present invention is to provide a lactic acid bacterium and a composition for improving the composition of intestinal microbial species, wherein the composition comprises the lactic acid bacterium and / or the exosomes secreted by the lactic acid bacterium. In addition, the composition for improving the composition of intestinal microbial species can be taken orally.
[0008] To achieve the above object, the present invention provides a novel lactic acid bacterium, which is Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under the deposit number NCIMB 44102.
[0009] Furthermore, the present invention provides a composition for improving the composition of intestinal microbial species, comprising an effective amount of extracellular vesicles, wherein the extracellular vesicles are secreted by a lactic acid bacterium, and the lactic acid bacterium is Pediococcus acidilactici deposited with the National Center for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under the deposit number NCIMB 44102.
[0010] The effective amount in the above composition of the present invention is a concentration of at least 10 8 The exosomes are selected from the group consisting of exosomes, microvesicles, ectosomes and apoptotic bodies.
[0011] In addition, the composition of the present invention has the ability to improve the composition of intestinal microbial species that may affect the course of Alzheimer's disease (AD).
[0012] Furthermore, the exosomes in the above-mentioned composition of the present invention can affect the growth of Firmicutes and / or Bacteroidetes.
[0013] Meanwhile, the exosomes may also affect the growth of at least one bacterial class, and the bacterial class is at least one selected from the group consisting of Bacteroidia, Clostridia and Bacilli.
[0014] Furthermore, the extracellular vesicles may affect the growth of at least one bacterial family, and the bacterial family is at least one selected from the group consisting of Lactobacillaceae, Muribaculaceae, Lachnospiraceae, Clostridiaceae, Desulfovibrionaceae, Erysipelotrichaceae, Eggerthellaceae, Akkermansiaceae, Ruminococcaceae and Eubacteriaceae. In addition, the extracellular vesicles may also affect the growth of Muribaculum and / or Lachnospira.
[0015] Furthermore, in the composition of the present invention as described above, the exosomes can promote the growth of Lactobacillus acidophilus.
[0016] In one embodiment, the present invention provides a nutritional supplement comprising Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under the accession number NCIMB44102.
[0017] In one embodiment, the present invention provides a food product comprising Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under the registration number NCIMB44102.
[0018] In one embodiment, the present invention provides a dietary supplement comprising Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under the accession number NCIMB44102.
[0019] In one embodiment, the present invention provides a food additive comprising Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under the registration number NCIMB44102.
[0020] In one embodiment, the present invention provides a pharmaceutical composition comprising Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under the accession number NCIMB44102.
[0021] In one embodiment, the present invention provides a feed comprising Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under the accession number NCIMB 44102.
[0022] Another object of the present invention is to provide a use of lactic acid bacteria for preparing a composition for improving the composition of intestinal microbial species, wherein the lactic acid bacteria is Pediococcus acidilactici deposited with the National Center for Food Industry and Marine Bacteria (NCIMB Ltd) of the United Kingdom under the accession number NCIMB 44102. In addition, the present invention further provides a use of novel lactic acid bacteria and / or the exosomes secreted therefrom for improving the composition of intestinal microbial species, wherein the lactic acid bacteria is Pediococcus acidilactici deposited with the National Center for Food Industry and Marine Bacteria (NCIMB Ltd) of the United Kingdom under the accession number NCIMB 44102.
[0023] Another object of the present invention is to provide an application of a composition for improving the composition of intestinal microbial strains, wherein the application includes products that are easy to use in daily life, such as food, beverages, health foods, additives, and medical compositions, for general people to take to achieve daily intestinal health care. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1A This is a photograph of the extracellular vesicles of the lactic acid bacteria of the present invention observed using a transmission electron microscope (TEM);
[0025] Figure 1B is a graph showing the average particle size distribution of the extracellular vesicles of the lactic acid bacteria of the present invention;
[0026] Figure 2 For APP NL-G-F / NL-G-F After the transgenic mice were orally administered with the lactic acid bacteria exosomes of the present invention, the relative abundance of intestinal microbial species in the mice;
[0027] Figure 3A and 3B It is a growth curve diagram of co-culture of lactic acid bacteria exosomes and Lactobacillus acidophilus of the present invention;
[0028] Figure 4A , 4B 4C and 4D are growth curves of co-culture of the lactic acid bacteria exosomes of the present invention and intestinal bacteria, such as Lachnospira and Ruminococcus;
[0029] Figure 5 It is a fluorescent staining image of the reaction between the lactic acid bacteria exosomes of the present invention and the microorganisms in mouse feces;
[0030] Fig. 6A The results of analyzing the intestinal microorganisms of mice without the addition of the lactic acid bacteria exosomes of the present invention by flow cytometry;
[0031] Figure 6B The results of analyzing the intestinal microorganisms of mice to which the lactic acid bacteria exosomes of the present invention were added by flow cytometry;
[0032] Figure 7 A histogram showing the relative abundance of species of intestinal microorganisms in mice that ingested the lactic acid bacteria exosomes of the present invention;
[0033] Figure 8 This is the evolutionary tree of Pediococcus acidilactici;
[0034] Fig. 9 The electrophoresis diagram of the amplification product using primers CGPA01_1590-F / R; and
[0035] Fig.10 This is the electrophoresis diagram of the product amplified by primer MA18 / 5M_850-F / R. DETAILED DESCRIPTION
[0036] All technical and scientific terms used in this specification, unless otherwise defined, have the meanings commonly understood by those with common knowledge in the art. The present invention will be illustrated by the following examples, which are only illustrative and not limiting. The present invention is not limited by the following examples. Unless otherwise specified, the materials used in the present invention are all commercially available and easily available. The following are only examples of available channels.
[0037] The present invention provides a novel lactic acid bacteria and a composition for improving the composition of intestinal microbial species, wherein the composition comprises the lactic acid bacteria and / or the exosomes secreted by the lactic acid bacteria, and the lactic acid bacteria is Pediococcus acidilactici deposited in the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) of the United Kingdom under the deposit number NCIMB 44102. The inventor of the present case learned through a transgenic mouse animal model of Alzheimer's disease (knock-in of the amyloid beta precursor protein gene (APP gene)) that the exosomes secreted by the Pediococcus acidilactici have a novel use or function of improving the composition of intestinal microbial species.
[0038] In addition, the Pediococcus acidilactici of the present invention is a novel lactic acid bacteria isolate obtained by the inventors of the present invention in the laboratory by screening from the intestinal tract of chickens.
[0039] The extracellular vesicles secreted by the lactic acid bacteria of the present invention were found to be effective in improving the richness of intestinal microorganisms in mice through analysis of the mouse animal model, that is, the extracellular vesicles can effectively improve the intestinal microbial species composition of Alzheimer's gene-transgenic mice, so that the intestinal microbial species composition of the gene-transgenic mice is restored to the same microbial species composition as that in a healthy state.
[0040] The aforementioned lactic acid bacteria isolates also include their successive cultured offspring or mutants, but still have the same bacterial characteristics, genomics, or uses (for improving the composition of intestinal microbial species) as those described in the present invention.
[0041] The composition described herein may include, but is not limited to: nutritional supplements, food products, dietary supplements, food additives, pharmaceutical compositions for animals and humans, feeds, beverages, health foods, animal drinking water additives, animal feed additives, beverage additives, and other product application forms suitable for the present invention.
[0042] The term "improvement" means that the composition of intestinal microbial species can be effectively improved compared to a composition not using the Pediococcus acidilactici and / or its extracellular vesicles, or containing the Pediococcus acidilactici and / or its extracellular vesicles of the present invention.
[0043] The term "effective amount" means an effective amount of active ingredients that can effectively improve, treat or restore one or more intestinal microbial species, or it can be called a "therapeutically effective amount" or "improvement effective amount". The term "pharmaceutically acceptable" means that the substance or composition must be compatible with other ingredients of the formulation and not harmful to the patient.
[0044] The composition of the present invention refers to a dosage form suitable for the composition of the present invention that can be prepared by the above-mentioned Pediococcus acidilactici and / or its extracellular vesicles and a pharmaceutically or food acceptable carrier using a technique well known to those skilled in the art; wherein the dosage form includes but is not limited to: solution, emulsion, suspension, powder, tablet, pill, lozenge, troche, capsule and other dosage forms similar to or suitable for the present invention.
[0045] The above composition may also be appropriately added with one or more dissolution aids, buffers, preservatives, colorants, spices, flavoring agents, excipients, etc. commonly used in the pharmaceutical field as needed.
[0046] In another preferred embodiment, the aforementioned composition provided by the present invention can be further added to an edible material to prepare a food product or a health product; wherein the edible material includes, but is not limited to: water; liquid milk product; milk; concentrated milk; fermented milk, such as yogurt, frozen yogurt, sour milk, lactic fermenting beverage; milk powder; ice cream; cream cheese; dry cheese; soybean milk; fermented soybean milk; fruit and vegetable juice; juice; sports drink; confectionery; jelly; baby food; health food; animal feed; herbal medicine; medicine); dietary supplement, etc.
[0047] Furthermore, the present invention also provides a method for improving the composition of intestinal microorganisms, which comprises providing an effective amount of the above-mentioned composition to patients with intestinal diseases or Alzheimer's disease to improve their intestinal microorganism composition.
[0048] In addition, the present invention also provides a method or use of the aforementioned Pediococcus acidilactici and / or the exosomes secreted therefrom for preparing a composition for improving the composition of intestinal microbial species.
[0049] The administration route of the composition provided by the present invention and the method for improving the intestinal microbial species composition thereof can be appropriately adjusted according to needs and is not particularly limited. The preferred administration route is oral administration of an appropriate dosage form.
[0050] Strain source
[0051] The Lactobacillus acidophilus used in the following examples of the present invention is a standard strain purchased from the Bioresource Collection and Research Center (BCRC) in Hsinchu, Taiwan: Lactobacillus acidophilus BCRC 14079. The Lachnospiraceae sp. and Ruminococcaceae sp. used in the present invention are standard strains purchased from the American Type Culture Collection (ATCC): Lachnospiraceae sp. TSD-26 and Ruminococcaceae sp. TSD-27. The novel lactic acid bacteria of the present invention are Pediococcus acidilactici obtained by laboratory screening from the intestinal tract of chickens, and deposited in the National Center for Food Industry and Marine Bacteria (NCIMB Ltd) of the United Kingdom under the deposit number NCIMB 44102.
[0052] Animal strains
[0053] The animal strain used in the following examples of the present invention is APP using the knock-in AD model of beta-amyloid precursor gene. NL-G-F / NL-G-F Transgenic mice (TG), in which the Swedish double mutant gene (KM670 / 671NL) and the Iberian mutant gene (I716F) were introduced into the Aβ sequence, increasing the amount of Aβ produced and the Aβ42 / 40 ratio. The transgenic mice began to show memory loss at 6 months of age, while the control group used C57BL / 6 (non-TG) mice as a control (Nilsson et al. ACS Chemical Neuroscience 2014, 5, 499-502).
[0054] Preparation of exosomes
[0055] First, the lactic acid Pediococcus of the present invention was cultured with MRS culture medium at 37°C for 24 hours, and the bacteria were removed by centrifugation at 10,000×g for 30 minutes. After the supernatant was filtered, the filtrate was subjected to ultracentrifugation at 247,537×g at 4°C, and then the supernatant was removed. The precipitate was washed with Dulbecco's phosphate buffered saline (DPBS), and the obtained washing solution was filtered with a 0.22 μm sterilization membrane, and then ultracentrifuged at 247,537×g at 4°C, and then the supernatant was removed. The precipitate was re-dissolved with DPBS to obtain extracellular vesicles and stored at -80°C (Choi et al. Experimental Neurobiology 2019, 28, 158-171).
[0056] Example 1 Morphological characteristics of extracellular vesicles secreted by Pediococcus acidilactici of the present invention
[0057] In this embodiment, the culture fluid of Pediococcus acidilactici of the present invention was centrifuged by ultracentrifugation to purify its extracellular vesicles (LAB-EV), and the morphological characteristics of the purified extracellular vesicles (LAB-EV) were observed by transmission microscopy. Figure 1A As shown, the exosomes are nanometer-sized spherical lipid bilayer structures. In addition, after the LAB-EV is appropriately diluted with Dulbecco's phosphate buffered saline (DPBS), it can be further analyzed by a nanoparticle tracking analyzer. The diluted liquid is irradiated with a laser light source, and the Brownian motion of the scattered light nanoparticles is observed under a microscope to calculate the average particle size and particle number (quantitative) of the LAB-EV sample. Figure 1B Shown is the average particle size distribution of the LAB-EV, and the average particle size of the LAB-EV is approximately 125 nanometers (nm).
[0058] Example 2 Relative abundance of intestinal microbial species in transgenic mice after oral administration of exosomes of Pediococcus acidilactici of the present invention
[0059] In this example, mice were orally administered with LAB-EVs once daily, and the mice were sacrificed 4 weeks after administration of LAB-EVs. The relative abundance of intestinal microbial species in the mice was then analyzed.
[0060] Figure 2The relative abundance of intestinal microbial species in mice after oral administration of the lactic acid Pediococcus exosomes (LAB-EV) of the present invention is shown, wherein Non-TG Veh: indicates oral administration of solvent by non-transgenic mice, n=6, TG Veh: indicates oral administration of solvent by transgenic mice (knock-in of Amyloid beta precursor protein gene (APP gene)), n=6, TG LAB-EV: indicates oral administration of LAB-EV by transgenic mice (knock-in of APP gene), n=6. Veh (Vehicle) here is DPBS, which is the solvent of LAB-EV.
[0061] Figure 2 The results showed that the top 10 families in terms of relative abundance in the intestinal flora of mice were Lactobacillaceae, Muribaculaceae, Lachnospiraceae, Clostridiaceae, Desulfovibrionaceae, Erysipelotrichaceae, Eggerthellaceae, Akkermansiaceae, Ruminococcaceae, and Eubacteriaceae. Figure 2 The results show that there are differences between the family-level microorganisms in the intestines of non-TG Veh mice and TG Veh mice, while the intestinal microbial composition of TG LAB-EV mice is closer to that of non-TG Veh mice; that is, the intestinal microbial species composition of transgenic mice improved after administration of LAB-EV, which also means that the intestinal microbial species composition of transgenic mice returned to be similar to that of normal mice. Therefore, LAB-EV can effectively improve the intestinal microbial species of transgenic mice and restore the intestinal microbial species composition of mice to the same microbial species composition as in a healthy state.
[0062] Example 3 Co-culture of exosomes of Pediococcus acidilactici and Lactobacillus acidophilus
[0063] In this example, an in vitro experiment was conducted to co-culture LAB-EV with Lactobacillus acidophilus to analyze whether the LAB-EV of the present invention has the potential to promote the growth of Lactobacillus acidophilus. LAB-EV was co-cultured with Lactobacillus acidophilus, and then the absorbance values at a wavelength of 600nm were measured at different time points, and finally the following values were obtained: Figure 3A and 3B The line graphs and histograms shown in the figure; the data of three replicates are expressed as mean ± standard error (SEM), and one-way analysis of variance was used, followed by Tukey's test for multiple group comparisons, and significant differences were marked with different English letters.
[0064] Depend on Figure 3A and 3B The results show that LAB-EV promotes the growth of Lactobacillus acidophilus, and the higher the concentration of LAB-EV, the better the effect of promoting the growth of Lactobacillus acidophilus. In other words, the effect of LAB-EV on promoting the growth of Lactobacillus acidophilus has a dose effect. 10 When LAB-EV with a concentration of 10 particles / mL was co-cultured with Lactobacillus acidophilus, the growth of Lactobacillus acidophilus was significantly increased. 8 When LAB-EV with a low particle number / mL was co-cultured with Lactobacillus acidophilus, the effect of promoting the growth of Lactobacillus acidophilus was second.
[0065] Example 4 Co-culture of exosomes of Pediococcus acidilactici and intestinal bacteria
[0066] In this example, LAB-EV was co-cultured with intestinal bacteria Lachnospiraceae sp. and Ruminococcaceae sp., and then the absorbance values at a wavelength of 600 nm were measured at different time points, and finally the following values were obtained: Figure 4A and 4C The line graph shown in the figure and the plate counts (Log CFU / mL) at different time points resulted in the following results: Figure 4B and 4D The histograms shown are: the data of three replicates are expressed as mean ± standard error (SEM), and different letters indicate significant differences (p < 0.05).
[0067] Depend on Figure 4A , 4BFrom the results shown in Figures 4C and 4D, it can be seen that LAB-EV has no effect on the growth of both intestinal bacteria Lachnospira and Ruminococcus, and that neither higher nor lower concentrations of LAB-EV have any effect on the growth of both intestinal bacteria Lachnospira and Ruminococcus.
[0068] Example 5 Fluorescence staining of the reaction between LAB-EV and mouse fecal microorganisms
[0069] In order to clarify whether intestinal microorganisms will ingest LAB-EVs and explore the types of intestinal bacteria that can ingest LAB-EVs, in this example, 10 8 LAB-EVs at 500 μg / ml were stained with CFSE (green), and mouse fecal bacteria were stained with DRAQ5 (red) and added to the wells; the CFSE excitation light was 492 nm, the divergence light was 517 nm, and the DRAQ5 excitation light was 647 nm, the divergence light was 665 nm, CFSE is carboxyfluoresceinsuccinimidyl ester, and DRAQ5 was purchased from Abcam (Bristol, UK).
[0070] See also Figure 5 The results shown are that the red fluorescence is the bacterial cells in the mouse feces stained with DRAQ5, and the cells have a rod-shaped or spherical distribution, and the green fluorescence is the LAB-EV stained with CFSE, and the overlapping area of the two is yellow. The test results show that LAB-EVs are taken into the cells by intestinal microorganisms, and the intestinal microorganisms are composed of a variety of bacteria. Some bacterial positions do not have green fluorescence overlap, indicating that not all types of bacteria will take in LAB-EVs, and only specific bacterial microorganisms will take in extracellular vesicles.
[0071] Example 6: LAB-EVs can be taken up by mouse intestinal bacteria
[0072] In this example, the intestinal microorganisms of mice without LAB-EV were respectively Fig. 6A ) and intestinal microbiota of mice with LAB-EV added ( Figure 6B ) was sent to the flow cytometer for analysis; the mouse intestinal microorganisms added with LAB-EVs refer to 10 10 Particles of LAB-EV were stained with CFSE and reacted with mouse intestinal bacteria in an anaerobic environment at 37°C, n = 6. CFSE is carboxyfluorescein succinimidyl ester.
[0073] See also Fig. 6AThe results shown, in which the intestinal microorganisms of mice without the addition of LAB-EVs were sent to a flow cytometer for analysis, the bacterial community was circled and this specific area was analyzed. It can be seen that the circled range includes cells of 1μm, 2μm and 10μm in size, and in the quadrant diagram, most of the intestinal microorganisms fall in the R8 quadrant and account for about 98.58% of the total bacterial community.
[0074] See also Figure 6B The results shown show that after the mouse intestinal microorganisms with LAB-EV added were sent to the flow cytometer, the range of bacterial presence was circled, which also included cells of 1μm, 2μm and 10μm in size. In the quadrant diagram, it can be seen that in addition to most of these cells falling in the R8 quadrant, 32.31% of the cells also fell in the R9 quadrant.
[0075] From the above results, it can be seen that the cell sizes in the selected range are 1μm, 2μm and 10μm, and this length is consistent with the bacterial size. By analyzing the intestinal microorganisms of mice without the addition of LAB-EV as the control group, it can be known that the mouse intestinal flora is in the range; and further, in the intestinal microorganisms added with fluorescently stained LAB-EV, a fluorescent reaction can be observed, indicating that some microorganisms in the mouse intestine have ingested LAB-EV, and about 32.31% of the bacteria in the mouse intestinal microorganisms will ingest LAB-EV.
[0076] Example 7 Clarifying the types of intestinal microorganisms in mice that ingested LAB-EVs
[0077] In this example, the intestinal microorganisms that ingest LAB-EVs in Example 6 are sorted out and sequenced. Figure 7 The results shown show that after sequencing, the intestinal microorganisms that react with LAB-EV include 1 kingdom, 9 phyla, 14 classes, 19 orders, 37 families, 74 genera and 87 species. Figure 7 The relative abundance histogram in the figure shows the proportion of bacteria in different taxonomic groups. All of them belong to the Bacteria kingdom, and most of them belong to the Firmicutes and Bacteroidetes, accounting for about 49% and 47% respectively. The classes are Bacteroidia accounting for 47%, Clostridia accounting for 44% and Bacilli accounting for 4%. The Lachnospiraceae family accounts for the largest proportion at 33%. The top two genera and species are Muribaculum / Muribaculum sp. (22%) and Lachnospira / Lachnospira sp. (19%).
[0078] For easy comparison, Figure 7The relative abundance histogram in the figure contains the following microorganisms in order: Bacteria; Proteobacteria, Bacteroidetes, Firmicutes; Bacilli, Clostridia, Bacteroidia; Lactobacillales, Clostridiales, Bacteroidales; Lactobacillaceae, Bacteroidaceae, Rikenellaceae, Ruminococcaceae, Prevotellaceae. llaceae), Lachnospiraceae; Alloprevotella, Rikenella, Butyricicoccus, ASF356, Ruminiclostridium, Alistipes, Lachnoclostridium, Roseburia, Lactobacillus, Bacteroides, Prevotella, Lachnospira, Muribaculaceae; Alloprevotella, Rikenella, Butyricicoccus, ASF356, Ruminiclostridium, Alistipes, Lachnoclostridium, Roseburia, Lactobacillus, Bacteroides, Prevotella, Lachnospira, Muribaculaceae; sp.), Rikenellaceae sp., Butyricicoccus sp., ASF356 sp., Ruminiclostridium sp., Lactobacillus sp., Alistipes sp., Lachnoclostridium sp., Roseburia sp., Bacteroides sp., Prevotellasp., Lachnospiraceae sp., Muribaculaceae sp.
[0079] In addition, as described above in the embodiments, the co-culture of LAB-EV and Lactobacillus acidophilus and the fluorescent staining experiments of LAB-EV and intestinal microorganisms showed that LAB-EV would be ingested by specific bacterial microorganisms, and the flow cytometer sorting experiment also found that about 32.31% of intestinal microorganisms would utilize LAB-EV. At the same time, further sequencing also found that Muribaculaceae and Lachnospiraceae were the two genera with the highest abundance among the microorganisms that ingested LAB-EV, at 22% and 19%, respectively.
[0080] Example 8 Identification of the novel Pediococcus acidilactici strain of the present invention
[0081] In this embodiment, the complete genome sequence of Pediococcus acidilactici of the present invention was analyzed by the second-generation MiSeq (Illumina, Inc., USA) and the third-generation MinION (Oxford Nanopore Technologies, Inc., UK) sequencing platforms, and the differences were found by comparing the genome databases (such as GenBank, Ensembl, BioCyc or RefSeq, etc.). The similarity between the genomes of 27 complete assemblies of the same species of Pediococcus acidilactici included in GenBank and the present invention was analyzed. As shown in Table 1 below, the average nucleotide similarity (Average nucleotide identity, ANI) with the present invention of Pediococcus acidilactici was calculated using FastANI v1.33. Figure 8 The evolutionary tree was calculated and drawn by Roary v 3.11.2 and FastTree2.1, which shows the relationship between different strains of Pediococcus acidilactici. Pediococcus acidilactici PB22 is the most similar strain to the present invention's Pediococcus acidilactici (ANI: 99.16%), and no strain of Pediococcus acidilactici with the same genome as the present invention was found.
[0082] Table 1. Average nucleotide similarity of the present invention's Pediococcus acidilactici and other Pediococcus acidilactici strains
[0083]
[0084]
[0085] Next, in order to effectively identify the DNA sequence of the present invention, the present embodiment distinguishes the same species of different strains of Pediococcus acidilactici by designing primers (Primers) that can identify the variable region of the genome, and these primers are summarized in the following Table 2. Table 3 shows the primer combination method and the amplified sequence of the target strain. After comparing the RefSeq database (the database includes the complete genome, scaffold and contig sequences), the primer combination CGPA01_1590-F / R used to identify the present invention of Pediococcus acidilactici amplified the sequence, and only the genome of Pediococcus acidilactici MA18 / 5M has the same fragment. The primer combination MA18 / 5M_850-F / R amplified the sequence, and only the genome of Pediococcus acidilactici MA18 / 5M has this fragment, and this fragment does not exist in the genome of the present invention of Pediococcus acidilactici.
[0086] Table 2. Specific identification primers
[0087] Primer Name Number Sequence ID Number CGPA01_1590-F 1 CGPA01_1590-R 2 MA18 / 5M_850-F 3 MA18 / 5M_850-R 4
[0088] Table 3. Amplified sequence fragments of CGPA01_1590-F / R and MA18 / 5M_850-F / R
[0089]
[0090] Next, the primer combination in Table 2 was subjected to polymerase chain reaction (PCR). The total reaction volume of PCR was 20 μl, containing 0.1 ng strain DNA, 500 nM primer, and 10 μl TaqDNA Polymerase Master Mix RED (Ampliqon A / S, DK). The reaction conditions of PCR were heating at 95°C for 2 min, then heating at 95°C for 20 sec, binding at 60°C for 30 sec, and extending at 72°C for 30 sec, and 30 cycles were performed under this condition; finally, extending at 72°C for 5 min. After the above PCR reaction was completed, the PCR product was taken out and electrophoresed for 40 min in 1.8% agarose, 1X TAE buffer solution, and 100 V voltage; then, the electrophoresis film was stained with SYBR Safe dye (Thermo Fisher Scientific, USA), and the stained electrophoresis film was placed in a blue light (470 nm) light box for observation, and photographed for archiving.
[0091] Table 4 shows strains used to confirm the unique sequence of the Pediococcus acidilactici strain of the present invention. Except for the present invention's Pediococcus acidilactici and MA18 / 5M, the strains listed were purchased from the Bioresource Collection and Research Center, Food Industry Research and Development Institute, and all of the strains belong to the genus Pediococcus, including Pediococcus pentosaceus, Pediococcus parvulus, and different strains of the same species. Pediococcus acidilactici MA18 / 5M (also known as R1001) was isolated from Jarro-Dophilus EPS (Jarrow Formulas, Inc.) products.
[0092] Table 4. Bacteria strain comparison table
[0093] Bacteria Strain ID / BCRC deposit number Pediococcus acidilactici Pediococcus acidilactici of the present invention Pediococcus acidilactici MA18 / 5M(R1001) Pediococcus acidilactici BCRC 11063 Pediococcus acidilactici BCRC 17599 Pediococcus acidilactici BCRC 80388 Pediococcus pentosaceus BCRC 10068 Pediococcus pentosaceus BCRC 11064 Pediococcus pentosaceus BCRC 12843 Pediococcus pentosaceus BCRC 14015 Pediococcus pentosaceus BCRC 14053 Pediococcus pentosaceus BCRC 14024 Pediococcus pentosaceus BCRC 14923 Pediococcus pentosaceus BCRC 80114 Pediococcus parvulus BCRC 12575
[0094] See also Fig. 9 , which is the electrophoresis diagram after PCR reaction with CGPA01_1590-F / R primers and Pediococcus strain DNA. Fig. 9 As shown, only the lactic acid bacteria of the present invention and MA18 / 5M showed a 115 bp bright band. Fig.10 , which uses MA18 / 5M_850-F / R primers to amplify the DNA of the lactic acid Pediococcus strain and MA18 / 5M of the present invention, and the electrophoresis diagram shows only a bright band at 505 bp in the lactic acid Pediococcus strain MA18 / 5M.
[0095] In summary, the genome analysis reveals the differences between the lactic acid Pediococcus of the present invention and the lactic acid Pediococcus strain, among which the lactic acid Pediococcus of the present invention has the highest genome similarity with PB22. The lactic acid Pediococcus of the present invention is distinguished from other disclosed Pediococcus strains by PCR and specific primers, and the primer combinations are CGPA01_1590-F / R and MA18 / 5M_850-F / R, respectively. CGPA01_1590-F / R only amplifies the lactic acid Pediococcus of the present invention and MA18 / 5M, but does not amplify other Pediococcus strains. Therefore, it is necessary to use the MA18 / 5M_850-F / R primer to further distinguish the lactic acid Pediococcus of the present invention from MA18 / 5M. The Pediococcus acidilactici of the present invention only showed a bright band amplified by the primers CGPA01_1590-F / R, while the Pediococcus acidilactici MA18 / 5M showed a bright band amplified by the primers CGPA01_1590-F / R and MA18 / 5M_850-F / R. In addition, the above genome analysis and PCR results show that the Pediococcus acidilactici SWP-CGPA01 provided by the present invention is a novel lactic acid bacteria isolate.
[0096] The above description has completely and clearly described the novel lactic acid bacteria of the present invention, the composition for improving the composition of intestinal microbial strains, and the products and uses of the lactic acid bacteria. It must be emphasized that the above detailed description is a specific description of the feasible embodiment of the present invention, but the embodiment is not used to limit the patent scope of the present invention. Any equivalent implementation or change that does not deviate from the technical spirit of the present invention should be included in the patent scope of this case.
[0097]
Biological material storage
[0098] The Pediococcus acidilactici of the present invention is deposited in the National Center for Food Industry and Marine Bacteria (NCIMB Ltd) of the United Kingdom, the deposit date is January 12, 2023, and the deposit number is NCIMB 44102.
Claims
1. A lactic acid bacterium, which is Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under the deposit number NCIMB 44102.
2. A composition for improving the composition of intestinal microbial species, It is characterized in that The invention comprises an effective amount of an extracellular vesicle, wherein the extracellular vesicle is secreted by a lactic acid bacterium, and the lactic acid bacterium is Pediococcus acidilactici deposited in the National Center for Food Industry and Marine Bacteria (NCIMB Ltd) of the United Kingdom with the deposit number NCIMB44102.
3. The composition according to claim 2, wherein the effective amount is a concentration of at least 10 8 The number of particles / mL of exosomes.
4. The composition according to claim 2, wherein the extracellular vesicles are any one selected from the group consisting of exosomes, microvesicles, ectosomes and apoptotic bodies. 5 . The composition according to claim 2 , which has the ability to improve the composition of intestinal microbial species that may affect the course of Alzheimer's disease (AD).
6. The composition according to claim 2, wherein the exosomes can affect the growth of Firmicutes and / or Bacteroidetes.
7. The composition according to claim 2, wherein the extracellular vesicles can affect the growth of at least one bacterial class, and the bacterial class is at least one selected from the group consisting of Bacteroidia, Clostridia and Bacilli.
8. The composition of claim 2, wherein the extracellular vesicles can affect the growth of at least one bacterial family, and the bacterial family is at least one selected from the group consisting of Lactobacillaceae, Muribaculaceae, Lachnospiraceae, Clostridiaceae, Desulfovibrionaceae, Erysipelotrichaceae, Eggerthellaceae, Akkermansiaceae, Ruminococcaceae and Eubacteriaceae.
9. The composition according to claim 2, wherein the extracellular vesicles can affect the growth of Muribaculum and / or Lachnospira.
10. The composition according to claim 2, wherein the exosomes can promote the growth of Lactobacillus acidophilus.
11. A nutritional supplement comprising Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.
12. A food product comprising Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.
13. A dietary supplement comprising Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.
14. A food additive comprising Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under the registration number NCIMB 44102.
15. A pharmaceutical composition comprising Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under the accession number NCIMB 44102.
16. A feed comprising Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under accession number NCIMB 44102.
17. Use of lactic acid bacteria for preparing a composition for improving the composition of intestinal microbial species, wherein the lactic acid bacteria is Pediococcus acidilactici deposited with the National Centre for Food Industry and Marine Bacteria (NCIMB Ltd) in the United Kingdom under the deposit number NCIMB 44102.
